API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 7 sources · 7 days · First seen · Last updated

Hims & Hers business expansion and market performance

Overview

Hims & Hers has implemented several strategic expansions to its telehealth platform. The company expanded its subscriber benefits program to include 14 partners, offering discounts on products such as Tonal strength training systems and Grüns gummies to support GLP-1 weight loss journeys.

In a significant expansion of the direct-to-consumer wellness market, Hims & Hers and Noom announced the launch of peptide-based treatment services. Hims & Hers introduced its Peptides+ platform, which offers five initial treatments: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine. These products are provided through licensed U.S. compounding pharmacies to support areas such as muscle growth, energy production, and anti-aging.

The company acknowledged that more research is needed regarding the efficacy of these treatments. Most of these compounded peptides have not been approved by the Food and Drug Administration (FDA) and lack randomized controlled trials to confirm safety and efficacy in humans. This move follows a shift in federal oversight, as the Department of Health and Human Services has highlighted these drugs.

Despite these developments and a 49% increase in third-quarter sales to $890.4 million, the company has faced stock volatility. Following its Q3 earnings report, Hims & Hers stock fell 17% after Q4 revenue guidance fell short of analyst expectations. The stock also saw a 2.93% decline during the period following the Peptides+ service launch.

Entities

Tonal · Hims & Hers Health, Inc. · Department of Health and Human Services · Viome · Food and Drug Administration

Timeline

  1. [BUSINESS] 5 sources
    Hims & Hers and Noom launch new peptide treatment services

    Telehealth leaders Hims & Hers and Noom are entering the peptide market with new services for muscle growth and anti-aging, despite a lack of FDA approval for many compounded formulations.

  2. [BUSINESS] 2 sources
    Hims & Hers expands benefits program amid stock volatility

    Hims & Hers expanded its GLP-1 support benefits program with new partners, even as its stock fell 17% following Q4 guidance that missed analyst expectations.

Sources

blockonomi.com · bustle.com · cryptocompass.com · fool.com · formosadeportiva.com.ar · modernretail.co · statnews.com

This summary has been updated 1 time: see revision history